MA’s ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004’s IRIS Phase 2 trial in autism spectrum disorderTopline results from both Phase 2 trials expected by mid-August 2026 ...
Wainwright Yu, a Big Tech executive, shares his journey with anxiety and ADHD, turning challenges into strengths throughout ...
Frontotemporal dementia causes striking shifts in behavior, emotion, and communication—making loved ones seem like different ...
Psychedelic therapy shows promise, but what makes its effects last? The answer may lie not in the drug, but in what happens ...
President Donald Trump holds up a signed executive order in the Oval Office of the White House on Saturday in Washington. (Julia Demaree Nikhinson | AP) President Trump has signed an executive order ...
April 18 (UPI) --President Donald Trump signed an executive order Saturday to accelerate research for some psychedelic drugs to treat mental health disorders. Surrounded by podcaster Joe Rogan and ...
A sweeping new study of psychiatric and genetic records has the potential to change treatment for millions of psychiatric patients, finding that many conditions involve similar genes and may not need ...
This retrospective, single‐center study included all patients aged 18 to 65 years who presented with ACS and underwent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results